Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun;34(2):341-358.
doi: 10.1016/j.idc.2020.02.009. Epub 2020 Apr 23.

Hepatitis B Virus Reactivation Potentiated by Biologics

Eiichi Ogawa  1 , Mike T Wei  2 , Mindie H Nguyen  3
Affiliations
Review

Hepatitis B Virus Reactivation Potentiated by Biologics

Eiichi Ogawa et al. Infect Dis Clin North Am. 2020 Jun.

Abstract

Hepatitis B virus (HBV) reactivation can be a serious complication for patients with chronic or resolved HBV infection when treated with biologics. For HBsAg-positive patients receiving biologics, the risk of HBV reactivation is moderate to high. HBsAg-negative/anti-HBc positive patients are at lower risk of HBV reactivation than HBsAg-positive patients. However, patients taking anti-CD20 agents, such as rituximab, have high risk of HBV reactivation (>10%), so antiviral prophylactic therapies are required. This review provides the different classes of biologics associated with HBV reactivation, stratifies the various reactivation risk levels by HBV status and biologic agent, and discusses management strategies.

Keywords: Hepatitis B virus; Nucleos(t)ide analogue; Prophylaxis; Reactivation.

PubMed Disclaimer

Conflict of interest statement

Disclosure M.H. Nguyen: Grant/research support: Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceutical; Advisory board/consultant: Dynavax Laboratories, Gilead Sciences, Intercept Pharmaceutical; Anylam Pharmaceutical; Roche Laboratories; and Novartis Pharmaceuticals. The other authors have nothing to disclose.

MeSH terms